SimBioSys® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022
06 Dec 2022
ImmunotherapyASCO
The company’s 4D tumor modeling™ technology is featured in six poster presentations showing the breath of its utility across surgical and medical oncology.
CHICAGO--(BUSINESS WIRE)-- SimBioSys, the precision oncology company behind the 4D Tumor Modeling™ technology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium (SABCS). SimBioSys will also exhibit at booth 823.
The studies covering six separate poster presentations at SABCS are based on data from both internal and external validation studies of SimBioSys’ proprietary platform. The results include collaborations with top cancer research institutions, multi-institutional analysis, enhanced visualization, and volumetric prediction capabilities to aid surgical planning as well as novel biomarkers.
“Our presentations at SABCS demonstrate our multidisciplinary approach and the clinical utility of our 4D modeling technology. We are incredibly proud of the research and clinical collaborations with key leaders in breast cancer and the impact our technology can have in breast cancer care,” said Dr. Anuja Antony, Chief Medical Officer of SimBioSys.
The company will be presenting abstracts validating their visualization and prediction technology which offers pCR prediction and recurrence free survival, surgical planning and biomarker development. Details about the presentations can be found below:
P1-04-07: pCR Score: a novel prognostic method to estimate the predictive probability of pCR in early-stage breast cancer patients
Peterson J, et. al.
When: Tuesday December 6, 2022
Where: Poster session 1 – Hall 1
Research conducted with: Berry Consultants, LLC; University of Chicago; Northwest Community Healthcare; Baylor Scott & White Health; University of Cincinnati; University of North Carolina, Lineberger Comprehensive Cancer CenterCancer Center; Springfield Clinic; University of Arizona Cancer CenterCancer Center.
P1-04-08: Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial
Kuzmiak C, et. al.
When: Tuesday December 6, 2022
Where: Poster session 1 – Hall 1
Research conducted with: University of North Carolina, Lineberger Comprehensive Cancer Center
P4-02-19: Development of a novel imaging biomarker to ascertain responsiveness to immunotherapy
Cook D, et. al.
When: Thursday December 8, 2022
Where: Poster session 2 – Hall 1
P4-02-24: A 3D visualization and prediction device for breast cancer surgeons and their patients
Parker A, et. al.
When: Thursday December 8, 2022
Where: Poster session 2 – Hall 1
P4-02-29: A 3D visualization method for breast cancer surgeons and patients
Parker A, et. al.
When: Thursday December 8, 2022
Where: Poster session 2 – Hall 1
P6-01-36: Validation of prognostic platform to further refine identification high risk patients indicated for chemotherapy free treatment in early-stage breast cancer
Peterson J, et. al.
When: Friday December 9, 2022
Where: Poster session 2 – Hall 1
Research conducted with: NorthShore University Health System.
About SimBioSys:
SimBioSys is a technology company deploying a combination of artificial intelligence and biophysics-based simulations to improve our understanding of cancer. By virtualizing cancer, SimBioSys aims to empower clinicians and patients with a comprehensive understanding of the disease and treatment options.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.